Julie Papanek Grant - 01 Feb 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: Director
Signature: /s/ Julie Papanek Grant
Issuer symbol: DAWN
Transactions as of: 01 Feb 2021
Net transactions value: +$208,000
Form type: 4
Filing time: 02 Jun 2021, 20:52:57 UTC
Next filing: 26 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Conversion of derivative security		+7,328,497	+226%		10,574,366	01 Jun 2021	By Canaan XI, L.P.	F1, F2
transaction	DAWN	Common Stock	Conversion of derivative security		+148,279	+1.4%		10,722,645	01 Jun 2021	By Canaan XI, L.P.	F2, F3
transaction	DAWN	Common Stock	Purchase	$208,000	+13,000	+0.12%	$16.00	10,735,645	01 Jun 2021	By Canaan XI, L.P.	F2
holding	DAWN	Common Stock						465,000	01 Feb 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DAWN	Series B Preferred Stock	Award		+148,279			148,279	01 Feb 2021	Common Stock	148,279		By Canaan XI, L.P.	F2, F4, F5
transaction	DAWN	Stock Option (right to buy Common Stock)	Award	$0	+63,000		$0.000000	63,000	26 May 2021	Common Stock	63,000	$16.00	Direct	F6, F7
transaction	DAWN	Series A Preferred Stock	Conversion of derivative security	$0	-7,328,497	-100%	$0.000000^*	0	01 Jun 2021	Common Stock	7,328,497		By Canaan XI, L.P.	F1, F2
transaction	DAWN	Series B Preferred Stock	Conversion of derivative security	$0	-148,279	-100%	$0.000000^*	0	01 Jun 2021	Common Stock	148,279		By Canaan XI, L.P.	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
F2	Represents securities held by Canaan XI, L.P. ("Canaan LP"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any.
F3	The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
F4	The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date.
F5	The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021.
F6	The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act.
F7	The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.